Treeline Biosciences CSO Jeffrey Engelman (L) and CEO Josh Bilenker
October 17, 2022 09:11 AM EDTUpdated 09:26 AM
Financing
Startups

Josh Bilenker, Jeff En­gel­man qui­et on every­thing be­hind their $735M 'outer edge' start­up

Kyle LaHucik

Senior Reporter

An $8 bil­lion ex­it from Eli Lil­ly and a short-lived stint head­ing up on­col­o­gy work at the Big Phar­ma post-Loxo sale have per­suad­ed Josh …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times